Market Cap 180.73M
Revenue (ttm) 30,000.00
Net Income (ttm) -51.63M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -172,100.01%
Debt to Equity Ratio 0.00
Volume 2,411,142
Avg Vol 1,665,308
Day's Range N/A - N/A
Shares Out 72.29M
Stochastic %K 53%
Beta 2.42
Analysts Strong Sell
Price Target $8.86

Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a a first-in-class monoclonal anti-human complement factor C5a antibody, which is in Phase 3 clinical trial for the treatment for patients suffering from early septic organ dysfunction, biological pro...

Industry: Biotechnology
Sector: Healthcare
Phone: 49 3641 508 180
Address:
Winzerlaer Str. 2, Jena, Germany
Dave1961
Dave1961 May. 13 at 4:28 PM
$IFRX what I see from LeviStrauss is that one- he’s a pretty doggone good skier but two - he may want to take some driving lessons or call an Uber next time.
1 · Reply
Monkey82
Monkey82 May. 13 at 4:15 PM
$IFRX Raymond James just upgraded IFRX from outperform to Strong Buy with $9 Target - buy before it's too late. https://www.tipranks.com/news/the-fly/inflarx-upgraded-to-strong-buy-from-outperform-at-raymond-james-thefly-news
0 · Reply
Barkingdogs
Barkingdogs May. 13 at 4:03 PM
$IFRX remember edsa 🤑
0 · Reply
Barkingdogs
Barkingdogs May. 13 at 4:02 PM
$IFRX picture of a stock going up 🤑 🤑 🤑
0 · Reply
Holten7575
Holten7575 May. 13 at 3:55 PM
$IFRX mm keeping a lid on this ---who you giving time to --let her rip
0 · Reply
MacGyverBud
MacGyverBud May. 13 at 3:48 PM
0 · Reply
FlowerInTheCellar
FlowerInTheCellar May. 13 at 3:33 PM
$IFRX What I find interesting now is that IFRX and Izicopan are no longer only appearing on stock market or biotech websites, but are now also being discussed on specialized AAV/patient platforms like ANCA Vasculitis News. To me, this shows that the story is slowly reaching the actual patient and disease community as well. What stood out to me there was that severe kidney patients were specifically mentioned together with the strong focus on safety and efficacy measurements. Severe kidney involvement is considered one of the most critical situations in AAV, so this point could be especially relevant for patients and treating physicians. The strong safety focus also does not seem random at all in the current Tavneos environment. Statements like “safer, faster and more convenient alternative” were also surprisingly open and confident in my opinion. Overall, I found it remarkable how concretely the topic is already being discussed there. https://ancavasculitisnews.com/news/phase-2-trial-planned-test-izicopan-aav/
1 · Reply
Barkingdogs
Barkingdogs May. 13 at 2:40 PM
$IFRX screaming buy under 3 🤑🤑
0 · Reply
Holten7575
Holten7575 May. 13 at 2:30 PM
$IFRX patience people ---takes time for bio to get out to the general market --still a great buy under $3.00 imho
0 · Reply
EdV3
EdV3 May. 13 at 2:12 PM
$IFRX well today's just closed thankfully now let's rally
0 · Reply
Latest News on IFRX
InflaRx Transcript: Investor update

May 8, 2026, 8:30 AM EDT - 5 days ago

InflaRx Transcript: Investor update


InflaRx to develop izicopan in AAV

2026-05-07T03:51:29.000Z - 6 days ago

InflaRx to develop izicopan in AAV


InflaRx announces new izicopan pre-clinical data

2026-05-04T12:09:26.000Z - 9 days ago

InflaRx announces new izicopan pre-clinical data


InflaRx to Report First Quarter 2026 Results on May 7, 2026

May 1, 2026, 7:30 AM EDT - 12 days ago

InflaRx to Report First Quarter 2026 Results on May 7, 2026


InflaRx assumed with an Outperform at Oppenheimer

2026-04-24T11:41:38.000Z - 19 days ago

InflaRx assumed with an Outperform at Oppenheimer


InflaRx announces new izicopan in vitro findings

2026-04-09T11:54:44.000Z - 4 weeks ago

InflaRx announces new izicopan in vitro findings


InflaRx presents vilobelimab data

2026-03-30T12:10:23.000Z - 6 weeks ago

InflaRx presents vilobelimab data


InflaRx price target lowered to $14 from $22 at Guggenheim

2026-03-20T11:20:14.000Z - 7 weeks ago

InflaRx price target lowered to $14 from $22 at Guggenheim


InflaRx reports FY25 EPS (EUR 0.68) vs. (EUR 0.78) last year

2026-03-19T11:35:54.000Z - 7 weeks ago

InflaRx reports FY25 EPS (EUR 0.68) vs. (EUR 0.78) last year


InflaRx to Report Full Year 2025 Results on March 19, 2026

Mar 12, 2026, 7:30 AM EDT - 2 months ago

InflaRx to Report Full Year 2025 Results on March 19, 2026


InflaRx Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 9:20 AM EDT - 2 months ago

InflaRx Transcript: Leerink Global Healthcare Conference 2026


InflaRx downgraded to Market Perform from Outperform at Leerink

2025-12-03T11:53:16.000Z - 5 months ago

InflaRx downgraded to Market Perform from Outperform at Leerink


InflaRx downgraded to Market Perform from Outperform at Leerink

2025-12-03T11:16:16.000Z - 5 months ago

InflaRx downgraded to Market Perform from Outperform at Leerink


Largest borrow rate increases among liquid names

2025-11-14T13:45:17.000Z - 6 months ago

Largest borrow rate increases among liquid names

GETY HPK JDST SGML UPXI


InflaRx price target raised to $8 from $3 at Cantor Fitzgerald

2025-11-11T11:20:32.000Z - 6 months ago

InflaRx price target raised to $8 from $3 at Cantor Fitzgerald


InflaRx price target raised to $9 from $2 at Raymond James

2025-11-11T11:16:27.000Z - 6 months ago

InflaRx price target raised to $9 from $2 at Raymond James


InflaRx price target raised to $7 from $3 at Oppenheimer

2025-11-11T11:15:24.000Z - 6 months ago

InflaRx price target raised to $7 from $3 at Oppenheimer


InflaRx price target raised to $24 from $3 at Lucid Capital

2025-11-10T21:11:57.000Z - 6 months ago

InflaRx price target raised to $24 from $3 at Lucid Capital


InflaRx Transcript: Status Update

Nov 10, 2025, 8:00 AM EST - 6 months ago

InflaRx Transcript: Status Update


InflaRx Transcript: Cantor Global Healthcare Conference 2025

Sep 4, 2025, 9:10 AM EDT - 8 months ago

InflaRx Transcript: Cantor Global Healthcare Conference 2025


InflaRx to Report Second Quarter 2025 Results on August 7, 2025

Jul 31, 2025, 7:30 AM EDT - 10 months ago

InflaRx to Report Second Quarter 2025 Results on August 7, 2025


InflaRx to Participate in Upcoming Investor Conferences

May 22, 2025, 7:30 AM EDT - 1 year ago

InflaRx to Participate in Upcoming Investor Conferences


InflaRx to Report First Quarter 2025 Results on May 7, 2025

Apr 30, 2025, 7:30 AM EDT - 1 year ago

InflaRx to Report First Quarter 2025 Results on May 7, 2025


InflaRx Announces Participation in September Investor Events

Aug 27, 2024, 7:30 AM EDT - 1 year ago

InflaRx Announces Participation in September Investor Events


InflaRx Hosts R&D Event Highlighting the Promise of INF904

Jun 5, 2024, 12:00 PM EDT - 2 years ago

InflaRx Hosts R&D Event Highlighting the Promise of INF904


Dave1961
Dave1961 May. 13 at 4:28 PM
$IFRX what I see from LeviStrauss is that one- he’s a pretty doggone good skier but two - he may want to take some driving lessons or call an Uber next time.
1 · Reply
Monkey82
Monkey82 May. 13 at 4:15 PM
$IFRX Raymond James just upgraded IFRX from outperform to Strong Buy with $9 Target - buy before it's too late. https://www.tipranks.com/news/the-fly/inflarx-upgraded-to-strong-buy-from-outperform-at-raymond-james-thefly-news
0 · Reply
Barkingdogs
Barkingdogs May. 13 at 4:03 PM
$IFRX remember edsa 🤑
0 · Reply
Barkingdogs
Barkingdogs May. 13 at 4:02 PM
$IFRX picture of a stock going up 🤑 🤑 🤑
0 · Reply
Holten7575
Holten7575 May. 13 at 3:55 PM
$IFRX mm keeping a lid on this ---who you giving time to --let her rip
0 · Reply
MacGyverBud
MacGyverBud May. 13 at 3:48 PM
0 · Reply
FlowerInTheCellar
FlowerInTheCellar May. 13 at 3:33 PM
$IFRX What I find interesting now is that IFRX and Izicopan are no longer only appearing on stock market or biotech websites, but are now also being discussed on specialized AAV/patient platforms like ANCA Vasculitis News. To me, this shows that the story is slowly reaching the actual patient and disease community as well. What stood out to me there was that severe kidney patients were specifically mentioned together with the strong focus on safety and efficacy measurements. Severe kidney involvement is considered one of the most critical situations in AAV, so this point could be especially relevant for patients and treating physicians. The strong safety focus also does not seem random at all in the current Tavneos environment. Statements like “safer, faster and more convenient alternative” were also surprisingly open and confident in my opinion. Overall, I found it remarkable how concretely the topic is already being discussed there. https://ancavasculitisnews.com/news/phase-2-trial-planned-test-izicopan-aav/
1 · Reply
Barkingdogs
Barkingdogs May. 13 at 2:40 PM
$IFRX screaming buy under 3 🤑🤑
0 · Reply
Holten7575
Holten7575 May. 13 at 2:30 PM
$IFRX patience people ---takes time for bio to get out to the general market --still a great buy under $3.00 imho
0 · Reply
EdV3
EdV3 May. 13 at 2:12 PM
$IFRX well today's just closed thankfully now let's rally
0 · Reply
EdV3
EdV3 May. 13 at 2:11 PM
$IFRX Gaps galore ☹️
0 · Reply
Barkingdogs
Barkingdogs May. 13 at 1:47 PM
$IFRX levi turning into a wrangler
0 · Reply
levystrauss
levystrauss May. 13 at 1:32 PM
4 · Reply
Barkingdogs
Barkingdogs May. 13 at 1:23 PM
$IFRX hoping to see a 3 today...the bell has been rung 🤑🤑🤑🤑
0 · Reply
Holten7575
Holten7575 May. 13 at 12:59 PM
$IFRX and now you see why the walk down the last few days --they wanted your shares
0 · Reply
Barkingdogs
Barkingdogs May. 13 at 11:58 AM
0 · Reply
Barkingdogs
Barkingdogs May. 13 at 11:55 AM
0 · Reply
GoCoogs
GoCoogs May. 13 at 11:54 AM
$IFRX IFRX InflaRx upgraded to Strong Buy from Outperform at Raymond James; tgt $9 (2.43)
0 · Reply
EdV3
EdV3 May. 13 at 11:45 AM
$IFRX https://www.streetinsider.com/dr/news.php?id=26481611&gfv=1 Can't see behind paywall but looks like rj upgraded and raised pt?
0 · Reply
Yoyo35
Yoyo35 May. 13 at 11:43 AM
$IFRX where ?🙂
0 · Reply
Barkingdogs
Barkingdogs May. 13 at 11:41 AM
$IFRX buy buy buy before bye bye
0 · Reply
Barkingdogs
Barkingdogs May. 13 at 11:32 AM
$IFRX bow wow 🤑🤑🤑🤑🤑
0 · Reply